Braveheart Bio, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Braveheart Bio, Inc. (BRVE) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-09-08.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-09-08
- Braveheart Bio, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Braveheart Bio, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-06-30 was $354.00K.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month |
|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-09-08 | $0.00 10-Q · filed 2026-09-08 |
| 2025-06-30 | $354.00K 10-Q · filed 2026-09-08 | $448.00K 10-Q · filed 2026-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |